PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis

Methods and conclusions for group’s report on the value and optimal pricing for Repatha and Praluent draw criticism from drug industry stakeholders, some policy experts. Approach includes cost-effectiveness review, novel US budget impact analysis.

A draft report aimed at facilitating payer negotiations on the price of the PCSK9 inhibitor drugs for cholesterol recommends dramatic discounts in the list prices of Amgen Inc.’s Repatha and Sanofi and Regeneron Pharmaceuticals Inc.’s Praluent based on a cost-effectiveness review and a novel US budget impact analysis.

The cost-effectiveness analysis indicates the price that “best represents the overall benefits these drugs may bring to patients” would be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America